Alzchem Group AG
AlzChem Group AG invests approx. EUR 11 million in the expansion of Creapure(R) capacities and precursors
DGAP-News: AlzChem Group AG
/ Key word(s): Market Report
AlzChem Group AG invests approx. EUR 11 million in the expansion of Creapure(R) capacities and precursors “With the planned investments, we will achieve further profitable growth. We will take advantage of our strong position in the premium creatine segment of the sports and health market. Likewise, we will benefit noticeably from our unique position as the quality leader ‘Made in Germany’,” explains Andreas Niedermaier, CEO of AlzChem Group AG. The sports and health market is a growth market that has grown significantly in recent years. Sports nutrition is increasingly expanding from competitive sports to users who focus on fitness and a healthy lifestyle. Accordingly, marketing activities for Creapure(R) are increasingly being extended to these users. At the same time, AlzChem is focusing on strategic partnerships, for example in Europe, in order to participate with Creapure(R) in the strong growth in the market for vegan and vegetarian foods. About AlzChem The company sees interesting growth prospects for itself especially in the areas of human and animal nutrition and agriculture. As a result of population growth, it is necessary to achieve efficient food production. Pharmaceutical raw materials and our creatine products can contribute to healthy aging as life expectancy increases. AlzChem is facing up to the goal of sustainability arising from climate change in the field of renewable energies and across the entire company. The fields of fine chemicals and metallurgy offer just as great a perspective. The broad product range of AlzChem Group AG includes dietary supplements, precursors for corona tests and pharmaceutical raw materials. These products are our company’s response to global trends and developments. AlzChem is ideally positioned in this regard and sees itself as well equipped for an environmentally oriented future and global developments. The company employs around 1,630 people at four production sites in Germany and one plant in Sweden, as well as two sales companies in the USA and China. In 2020, AlzChem generated consolidated sales of around EUR 379 million and EBITDA of around EUR 53.8 million. Contact: Sabine Sieber Head of Investor Relations & Communications
09.08.2021 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English |
Company: | AlzChem Group AG |
Dr.-Albert-Frank-Str. 32 | |
83308 Trostberg | |
Germany | |
Phone: | +498621862888 |
Fax: | +49862186502888 |
E-mail: | ir@alzchem.com |
Internet: | www.alzchem.com |
ISIN: | DE000A2YNT30 |
WKN: | A2YNT3 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Stuttgart |
EQS News ID: | 1225023 |
End of News | DGAP News Service |